• No results found

[PDF] Top 20 A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer

Has 10000 "A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer" found on our website. Below are the top 20 most common "A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer".

A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer

A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer

... when panitumumab is given in the refractory set- ting ...study, panitumumab was most commonly given with FOLFIRI and there was some evidence that therapy can be de-escalated to a sin- gle agent in patients ... See full document

8

Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study.

Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study.

... wild-type metastatic colorectal cancer, outcomes were comparable whether patients received the epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) or the vascular ... See full document

7

Treatment of metastatic colorectal cancer: focus on panitumumab

Treatment of metastatic colorectal cancer: focus on panitumumab

... of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with ... See full document

10

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

... with metastatic colorectal cancer irrespective of RAS and BRAF molecular ...or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an ... See full document

8

Profile of panitumumab as first-line treatment in patients with wild-type <em>KRAS</em> metastatic colorectal cancer

Profile of panitumumab as first-line treatment in patients with wild-type <em>KRAS</em> metastatic colorectal cancer

... with metastatic colorectal cancer ...mCRC. Panitumumab is a fully humanized monoclonal antibody against ...of panitumumab in combination with a chemotherapy backbone, in the first line ... See full document

12

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

... Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid ...of panitumumab has been tested in vitro ... See full document

16

FOLFIRI plus panitumumab in the treatment of wild type KRAS and wild type NRAS metastatic colorectal cancer

FOLFIRI plus panitumumab in the treatment of wild type KRAS and wild type NRAS metastatic colorectal cancer

... of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal ...with metastatic colorectal cancer (FIRE-3): a randomised, open- label, phase 3 ... See full document

7

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

... Of the 37 evaluable patients, one demonstrated a false negative KRAS codon 12 mutation and an additional two patients did not have sufficient primary tumor nucleic acid isolation; these patients were removed from ... See full document

12

Comparative effectiveness and safety of monoclonal antibodies (Bevacizumab, Cetuximab, and Panitumumab) in combination with chemotherapy for metastatic colorectal cancer : a systematic review and meta-analysis

Comparative effectiveness and safety of monoclonal antibodies (Bevacizumab, Cetuximab, and Panitumumab) in combination with chemotherapy for metastatic colorectal cancer : a systematic review and meta-analysis

... Within Brazil, any modest improvement in effectiveness, coupled with a significant increase in severe adverse events with BEVA, needs to be balanced against the increasing number of successful litigations as well as the ... See full document

22

The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials

The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials

... of panitumumab to chemotherapy in the treatment of ...“colorectal cancer” [All ...without panitumumab; and 4) outcome measure, OS, progression-free survival (PFS), and overall response rate ... See full document

8

&lt;p&gt;The impact of panitumumab treatment on survival and quality of life in patients with &lt;em&gt;RAS&lt;/em&gt; wild-type metastatic colorectal cancer&lt;/p&gt;

<p>The impact of panitumumab treatment on survival and quality of life in patients with <em>RAS</em> wild-type metastatic colorectal cancer</p>

... either panitumumab or cetuximab, supporting the role of HER2 ampli fi cation as a resistance mechanism to anti- ...(ie panitumumab plus the mTOR inhibitor everolimus; 68 or panitumumab plus BRAF and ... See full document

14

Patient considerations in metastatic colorectal cancer &amp;ndash; role of panitumumab

Patient considerations in metastatic colorectal cancer &ndash; role of panitumumab

... $2 panitumumab skin toxicities existed if patients were given preemptive treatment (48 patients) vs reactive treatment after the skin toxicity developed (47 patients) over a 6-week ...first panitumumab ... See full document

12

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy

... the colorectal carcinogenesis, inactiva- tion of tumor suppressor PTEN could be potentially related to cetuximab ...to colorectal carcinogenesis, the activating mutations in KRAS are furthermore clearly ... See full document

9

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

... Colorectal cancer (CRC) is the third most common cancer type ...common cancer type with 3–6% increasing morbidity each year ...of metastatic CRC to 30  ... See full document

11

Prognostic factors of survival in patients treated with nab- paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

Prognostic factors of survival in patients treated with nab- paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

... Pancreatic cancer (PC) is an aggressive tumor that accounts for approximately 3% of all cancers, whose incidence is increasing ...of cancer death in the United States in both ...or metastatic disease ... See full document

6

Organ Preservation in Bilharzial Bladder Cancer in Egypt: Single Institutional Experience

Organ Preservation in Bilharzial Bladder Cancer in Egypt: Single Institutional Experience

... bladder cancer and used in combination with platinum as a standard of care in the neoadjuvant and metastatic settings ...various cancer cell lines, including lines derived from bladder tumors ... See full document

7

Comparison of Oncologic Outcomes in Laparoscopic versus Open Surgery for Non-Metastatic Colorectal Cancer: Personal Experience in a Single Institution

Comparison of Oncologic Outcomes in Laparoscopic versus Open Surgery for Non-Metastatic Colorectal Cancer: Personal Experience in a Single Institution

... 4. Guillou, P.J.; Quirke, P.; Thorpe, H.; Walker, J.; Jayne, D.G.; Smith, A.M.; Heath, R.M.; Brown, J.M.; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients ... See full document

24

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

... Results: Median age was 59.6 years (range 35–79); male/female ratio was 54%/46%; World Health Organization performance status 0/1/2–3 was 33%/55%/11%, respectively; and the number of metastatic sites, ... See full document

8

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

... with panitumumab in the PRIME study, therefore, the impact of rash-related events may have been balanced by favourable antitumour treatment-related ...advanced cancer may consider skin rash to be part of ... See full document

7

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

... of cancer that histological different types of cancer could share the same dysregulated signaling pathway(s) and one particu- lar type of cancer could have multiple genetic abnormali- ... See full document

13

Show all 10000 documents...